

Michelle M Epstein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4671985/publications.pdf>

Version: 2024-02-01

87
papers

2,412
citations

236925

25
h-index

223800

46
g-index

89
all docs

89
docs citations

89
times ranked

3303
citing authors

#	ARTICLE	IF	CITATIONS
1	Scientific Opinion on development needs for the allergenicity and protein safety assessment of food and feed products derived from biotechnology. EFSA Journal, 2022, 20, e07044.	1.8	20
2	Statement complementing the EFSA Scientific Opinion on the assessment of genetically modified oilseed rape MS11 for food and feed uses, import and processing, under Regulation (EC) No 1829/2003 (application EFSA-GMO-2016-138). EFSA Journal, 2022, 20, e07190.	1.8	2
3	Assessment of genetically modified maize DP4114-AMON 810-AMIR604-ANK603 and subcombination food and feed uses, under Regulation (EC) No 1829/2003 (application EFSA-GMO-NL-2018-150). EFSA Journal, 2022, 20, e07134.	1.8	5
4	Assessment of genetically modified maize MON88017-AMON810 for renewal authorisation under Regulation (EC) No 1829/2003 (application EFSA-GMO-017). EFSA Journal, 2021, 19, e06375.	1.8	2
5	Statement on in vitro protein digestibility tests in allergenicity and protein safety assessment of genetically modified plants. EFSA Journal, 2021, 19, e06350.	1.8	32
6	Assessment of genetically modified maize MON 87427 - MON 87460 - MON 89034 - 1507 - MON 87411 - 59122 and subcombinations, for food and feed uses, under Regulation (EC) No 1829/2003 (application) Tj ETQq0 0.0 r gBT /@verlock 10	1.8	10
7	Assessment of genetically modified maize 1507 - MIR162 - MON810 - ANK603 and subcombinations, for food and feed uses, under Regulation (EC) No 1829/2003 (application EFSA-GMO-NL-2015-127). EFSA Journal, 2021, 19, e06348.	1.8	10
8	Assessment of genetically modified soybean GMB151 for food and feed uses, under Regulation (EC) No 1829/2003 (application EFSA-GMO-NL-2018-153). EFSA Journal, 2021, 19, e06424.	1.8	3
9	Statement complementing the EFSA Scientific Opinion on application (EFSA-GMO-NL-2010-85) for authorisation of food and feed containing, consisting of and produced from genetically modified soybean MON 87769 - MON 89788. EFSA Journal, 2021, 19, e06589.	1.8	1
10	Assessment of genetically modified oilseed rape 73496 for food and feed uses, under Regulation (EC) No 1829/2003 (application EFSA-GMO-NL-2012-109). EFSA Journal, 2021, 19, e06610.	1.8	3
11	Assessment of genetically modified cotton GHB811 for food and feed uses, under Regulation (EC) No 1829/2003 (application EFSA-GMO-ES-2018-154). EFSA Journal, 2021, 19, e06781.	1.8	2
12	In vivo and in vitro random mutagenesis techniques in plants. EFSA Journal, 2021, 19, e06611.	1.8	13
13	Assessment of genetically modified maize NK603 - T25 - DAS-40278-9 and subcombinations, for food and feed uses, under Regulation (EC) No 1829/2003 (application EFSA-GMO-NL-2019-164). EFSA Journal, 2021, 19, e06942.	1.8	8
14	Overview of in vivo and ex vivo endpoints in murine food allergy models: Suitable for evaluation of the sensitizing capacity of novel proteins?. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 289-301.	5.7	28
15	Adequacy and sufficiency evaluation of existing EFSA guidelines for the molecular characterisation, environmental risk assessment and post-market environmental monitoring of genetically modified insects containing engineered gene drives. EFSA Journal, 2020, 18, e06297.	1.8	23
16	Assessment of genetically modified oilseed rape GT73 for renewal authorisation under Regulation (EC) No 1829/2003 (application EFSA-GMO-002). EFSA Journal, 2020, 18, e06199.	1.8	2
17	Statement complementing the EFSA Scientific Opinion on application (EFSA-GMO-NL-2009-675) for placing on the market of genetically modified oilseed rape Ms8 - Rf3 - GT73 and subcombinations, which have not been authorised previously (i.e. Ms8 - GT73 and Rf3 - GT73) independently of their origin, for food and feed uses, import and processing, with the exception of isolated seed protein for food, under Regulation (EC) No 1829/2003 (application EFSA-GMO-NL-2009-675). EFSA Journal, 2020, 18, e06200.	1.8	0
18	Immunological Outcomes of Allergen-Specific Immunotherapy in Food Allergy. Frontiers in Immunology, 2020, 11, 568598.	4.8	53

#	ARTICLE	IF	CITATIONS
19	COST Action ImpARAS™: what have we learnt to improve food allergy risk assessment. A summary of a 4-year networking consortium. <i>Clinical and Translational Allergy</i> , 2020, 10, 13.	3.2	19
20	Assessment of genetically modified soybean MON87705–MON87708–MON89788, for food and feed uses, under Regulation (EC) No 1829/2003 (application EFSA-GMO-NL-2015-126). <i>EFSA Journal</i> , 2020, 18, e06111.	1.8	5
21	Assessment of genetically modified soybean SYHT0H2 for food and feed uses, import and processing, under Regulation (EC) No 1829/2003 (application EFSA-GMO-DE-2012-111). <i>EFSA Journal</i> , 2020, 18, e05946.	1.8	10
22	Assessment of genetically modified maize MON88017 for renewal authorisation under Regulation (EC) No 1829/2003 (application EFSA-GMO-RX-014). <i>EFSA Journal</i> , 2020, 18, e06008.	1.8	1
23	Assessment of genetically modified oilseed rape MS11 for food and feed uses, import and processing, under Regulation (EC) No 1829/2003 (application EFSA-GMO-BE-2016-138). <i>EFSA Journal</i> , 2020, 18, e06112.	1.8	3
24	Assessment of genetically modified maize MZIR098 for food and feed uses, under Regulation (EC) No 1829/2003 (application EFSA-GMO-DE-2017-142). <i>EFSA Journal</i> , 2020, 18, e06171.	1.8	8
25	Preclinical biological and physicochemical evaluation of two-photon engineered 3D biomimetic copolymer scaffolds for bone healing. <i>Biomaterials Science</i> , 2020, 8, 1683-1694.	5.4	8
26	Applicability of the EFSA Opinion on site-directed nucleases type 3 for the safety assessment of plants developed using site-directed nucleases type 1 and 2 and oligonucleotide-directed mutagenesis. <i>EFSA Journal</i> , 2020, 18, e06299.	1.8	31
27	Scientific Opinion on application EFSA-GMO-NL-2016-132 for authorisation of genetically modified of insect-resistant and herbicide-tolerant soybean DAS-81419-2–DAS-44406-6 for food and feed uses, import and processing submitted in accordance with Regulation (EC) No 1829/2003 by Dow Agrosciences LLC. <i>EFSA Journal</i> , 2020, 18, e06302.	1.8	4
28	Assessment of genetically modified maize MON 87427–MON 89034–MIR162–ANK603 and subcombinations, for food and feed uses, under Regulation (EC) No 1829/2003 (application EFSA-GMO-NL-2016-131). <i>EFSA Journal</i> , 2019, 17, e05734.	1.8	9
29	Assessment of genetically modified maize MON 87427–MON 87460–MON 89034–MIR162–ANK603 and subcombinations, for food and feed uses, under Regulation (EC) No 1829/2003 (application) Tj ETQq1 1 0.784314.gBT /Overlock 10	1.8	1
30	Assessment of genetically modified maize MIR604 for renewal authorisation under Regulation (EC) No 1829/2003 (application EFSA-GMO-RX-013). <i>EFSA Journal</i> , 2019, 17, e05846.	1.8	3
31	Assessment of genetically modified maize MON89034–1507–MON88017–59122–DAS40278-9 and subcombinations independently of their origin for food and feed uses, import and processing under Regulation (EC) No 1829/2003 (application EFSA-GMO-NL-2013-113). <i>EFSA Journal</i> , 2019, 17, e05521.	1.8	6
32	Assessment of genetically modified maize Bt11–MIR162–MIR604–1507–5307–GA21 and subcombinations, for food and feed uses, under Regulation (EC) No 1829/2003 (application EFSA-GMO-DE-2011-103). <i>EFSA Journal</i> , 2019, 17, e05635.	1.8	7
33	Ragweed pollen and allergic symptoms in children: Results from a three-year longitudinal study. <i>Science of the Total Environment</i> , 2019, 683, 240-248.	8.0	18
34	The relevance of a digestibility evaluation in the allergenicity risk assessment of novel proteins. Opinion of a joint initiative of COST action ImpARAS and COST action INFOGEST. <i>Food and Chemical Toxicology</i> , 2019, 129, 405-423.	3.6	67
35	Assessment of genetically modified oilseed rape T45 for renewal of authorisation under Regulation (EC) No 1829/2003 (application EFSA-GMO-RX-012). <i>EFSA Journal</i> , 2019, 17, e05597.	1.8	0
36	Connecting experts in the agricultural and meteorological sciences to advance knowledge of pest management in a changing climate. <i>Science of the Total Environment</i> , 2019, 673, 694-698.	8.0	4

#	ARTICLE	IF	CITATIONS
37	Th2-TRMs Maintain Life-Long Allergic Memory in Experimental Asthma in Mice. <i>Frontiers in Immunology</i> , 2019, 10, 840.	4.8	35
38	Assessment of genetically modified maize MON89034-1507-ANK603-DAS40278-9 and subcombinations independently of their origin for food and feed uses, import and processing, under Regulation (EC) No 1829/2003 (application EFSA-GMO-NL-2013-112). <i>EFSA Journal</i> , 2019, 17, e05522.	1.8	6
39	Statement complementing the EFSA Scientific Opinion on application (EFSA-GMO-UK-2006-34) for authorisation of food and feed containing, consisting of and produced from genetically modified maize 3272. <i>EFSA Journal</i> , 2019, 17, e05844.	1.8	3
40	Assessment of genetically modified maize MON89034 for renewal authorisation under Regulation (EC) No 1829/2003 (application EFSA-GMO-RX-015). <i>EFSA Journal</i> , 2019, 17, e05845.	1.8	4
41	Assessment of genetically modified maize MON87427-MON89034-MIR162-MON87411 and subcombinations, for food and feed uses, under Regulation (EC) No 1829/2003 (application) Tj ETQq1 1 0.784314.rgBT/Overlock 10	1.8	1
42	Assessment of genetically modified soybean MON87751-MON87701-MON87708-MON89788 for food and feed uses, under Regulation (EC) No 1829/2003 (application EFSA-GMO-NL-2016-128). <i>EFSA Journal</i> , 2019, 17, e05847.	1.8	9
43	Preface to the special issue of Food and Chemical Toxicology on the outcomes of the MARLON project on veterinary epidemiology of potential health impacts of genetically modified feeds in livestock. <i>Food and Chemical Toxicology</i> , 2018, 117, 1-2.	3.6	0
44	Biocompatibility and immunogenicity of elastin-like recombinamer biomaterials in mouse models. <i>Journal of Biomedical Materials Research - Part A</i> , 2018, 106, 924-934.	4.0	13
45	Assessment of genetically modified soybean MON89788 for renewal of authorisation under Regulation (EC) No 1829/2003 (application EFSA-GMO-RX-011). <i>EFSA Journal</i> , 2018, 16, e05468.	1.8	3
46	Assessment of genetically modified LLCotton25 for renewal of authorisation under Regulation (EC) No 1829/2003 (application EFSA-GMO-RX-010). <i>EFSA Journal</i> , 2018, 16, e05473.	1.8	0
47	Assessment of genetically modified maize MZHGOJG for food and feed uses, import and processing under Regulation (EC) No 1829/2003 (application EFSA-GMO-DE-2016-133). <i>EFSA Journal</i> , 2018, 16, e05469.	1.8	7
48	Biological Compatibility Profile on Biomaterials for Bone Regeneration. <i>Journal of Visualized Experiments</i> , 2018, , .	0.3	4
49	Modifiable Risk Factors for Common Ragweed (<i>Ambrosia artemisiifolia</i>) Allergy and Disease in Children: A Case-Control Study. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 1339.	2.6	7
50	An Opinion on non-human primates testing in Europe. <i>Drug Discovery Today: Disease Models</i> , 2017, 23, 5-9.	1.2	3
51	Guidance on allergenicity assessment of genetically modified plants. <i>EFSA Journal</i> , 2017, 15, e04862.	1.8	109
52	The Use of Mouse Asthma Models to Successfully Discover and Develop Novel Drugs. <i>International Archives of Allergy and Immunology</i> , 2017, 173, 61-70.	2.1	5
53	Climate Change and Future Pollen Allergy in Europe. <i>Environmental Health Perspectives</i> , 2017, 125, 385-391.	6.0	216
54	Current challenges facing the assessment of the allergenic capacity of food allergens in animal models. <i>Clinical and Translational Allergy</i> , 2016, 6, 21.	3.2	46

#	ARTICLE	IF	CITATIONS
55	Scientific Opinion on Risk Assessment of Synthetic Biology. Trends in Biotechnology, 2016, 34, 601-603.	9.3	27
56	Revealing the acute asthma ignorome: characterization and validation of uninvestigated gene networks. Scientific Reports, 2016, 6, 24647.	3.3	20
57	A review of animal models used to evaluate potential allergenicity of genetically modified organisms (GMOs). Drug Discovery Today: Disease Models, 2015, 17-18, 81-88.	1.2	6
58	Experimental food allergy models to study the role of innate immune cells as initiators of allergen-specific Th2 immune responses. Drug Discovery Today: Disease Models, 2015, 17-18, 55-62.	1.2	5
59	Effects of climate change and seed dispersal on airborne ragweed pollen loads in Europe. Nature Climate Change, 2015, 5, 766-771.	18.8	147
60	The methyltransferase Setdb2 mediates virus-induced susceptibility to bacterial superinfection. Nature Immunology, 2015, 16, 67-74.	14.5	120
61	Non-Invasive Optical Imaging of Eosinophilia during the Course of an Experimental Allergic Airways Disease Model and in Response to Therapy. PLoS ONE, 2014, 9, e90017.	2.5	13
62	No Adjuvant Effect of Bacillus thuringiensis-Maize on Allergic Responses in Mice. PLoS ONE, 2014, 9, e103979.	2.5	17
63	Tiotropium bromide inhibits relapsing allergic asthma in BALB/c mice. Pulmonary Pharmacology and Therapeutics, 2014, 27, 44-51.	2.6	32
64	Genetically Modified β -Amylase Inhibitor Peas Are Not Specifically Allergenic in Mice. PLoS ONE, 2013, 8, e52972.	2.5	30
65	Dendritic Polyglycerolsulfate Near Infrared Fluorescent (NIRF) Dye Conjugate for Non-Invasively Monitoring of Inflammation in an Allergic Asthma Mouse Model. PLoS ONE, 2013, 8, e57150.	2.5	34
66	Comparison of the β -Amylase Inhibitor-1 from Common Bean (<i>Phaseolus vulgaris</i>) Varieties and Transgenic Expression in Other Legumes—Post-Translational Modifications and Immunogenicity. Journal of Agricultural and Food Chemistry, 2011, 59, 6047-6054.	5.2	25
67	Fate of Transgenic DNA from Orally Administered Bt MON810 Maize and Effects on Immune Response and Growth in Pigs. PLoS ONE, 2011, 6, e27177.	2.5	70
68	Treatment of allergic asthma: Modulation of Th2 cells and their responses. Respiratory Research, 2011, 12, 114.	3.6	158
69	A Comparative Approach Linking Molecular Dynamics of Altered Peptide Ligands and MHC with In Vivo Immune Responses. PLoS ONE, 2010, 5, e11653.	2.5	31
70	Conditional Deletion of Histone Deacetylase 1 in T Cells Leads to Enhanced Airway Inflammation and Increased Th2 Cytokine Production. Journal of Immunology, 2010, 185, 3489-3497.	0.8	126
71	The Protein Tyrosine Kinase Tec Regulates a CD44 ^{high} CD62L ^{hi} Th17 Subset. Journal of Immunology, 2010, 185, 5111-5119.	0.8	20
72	Long-Term Deposition of Inhaled Antigen in Lung Resident CD11b ^{hi} CD11c ⁺ Cells. American Journal of Respiratory Cell and Molecular Biology, 2007, 36, 435-441.	2.9	12

#	ARTICLE	IF	CITATIONS
73	Activin A is an acute allergen-responsive cytokine and provides a link to TGF- β -mediated airway remodeling in asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 117, 111-118.	2.9	108
74	Are mouse models of allergic asthma useful for testing novel therapeutics?. <i>Experimental and Toxicologic Pathology</i> , 2006, 57, 41-44.	2.1	25
75	Targeting memory Th2 cells for the treatment of allergic asthma. , 2006, 109, 107-136.		41
76	A Novel Low Molecular Weight Inhibitor of Dendritic Cells and B Cells Blocks Allergic Inflammation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 173, 599-606.	5.6	41
77	Ephrin-A1 Suppresses Th2 Cell Activation and Provides a Regulatory Link to Lung Epithelial Cells. <i>Journal of Immunology</i> , 2004, 172, 843-850.	0.8	37
78	Repeated Aerosol Allergen Exposure Suppresses Inflammation in B-Cell-Deficient Mice with Established Allergic Asthma. <i>International Archives of Allergy and Immunology</i> , 2004, 133, 40-48.	2.1	23
79	Modeling allergic asthma: from in vitro assays to virtual patients. <i>Drug Discovery Today: Disease Models</i> , 2004, 1, 387-394.	1.2	6
80	Do Mouse Models of Allergic Asthma Mimic Clinical Disease?. <i>International Archives of Allergy and Immunology</i> , 2004, 133, 84-100.	2.1	136
81	Inhaled dexamethasone differentially attenuates disease relapse and established allergic asthma in mice. <i>Clinical Immunology</i> , 2004, 110, 13-21.	3.2	15
82	Long-Lived Th2 Memory in Experimental Allergic Asthma. <i>Journal of Immunology</i> , 2002, 169, 4788-4796.	0.8	98
83	Recurrent Aerosol Antigen Exposure Induces Distinct Patterns of Experimental Allergic Asthma in Mice. <i>Clinical Immunology</i> , 2002, 102, 145-153.	3.2	22
84	Systemic Administration of Antigen-Pulsed Dendritic Cells Induces Experimental Allergic Asthma in Mice upon Aerosol Antigen Rechallenge. <i>Clinical Immunology</i> , 2002, 103, 176-184.	3.2	27
85	The role of diet in the treatment of a patient with urticaria and urticarial vasculitis. <i>Journal of Allergy and Clinical Immunology</i> , 1992, 90, 414-415.	2.9	7
86	Cyclosporine-Induced Thrombotic Microangiopathy Resulting in Renal Allograft Loss and Its Successful Reuse: A Report of Two Cases. <i>American Journal of Kidney Diseases</i> , 1991, 17, 346-348.	1.9	11
87	The usefulness of routine screening for salivary secretory component. <i>Journal of Allergy and Clinical Immunology</i> , 1991, 88, 356-360.	2.9	5